Science Advisory Committee on Health Products Containing Cannabis
On this page
As part of the development of the Cannabis Regulations in 2018, Health Canada committed to holding consultations about a potential approach for non-prescription health products containing cannabis. This consultation was held from June 19, 2019 to September 3, 2019.
The purpose of this consultation was to seek feedback from Canadians, as well as the cannabis and health products industries, regarding the kinds of products they would be interested in manufacturing, selling or purchasing, should a legal pathway to market for these products be established. As part of this consultation, the Department made a commitment to seek external scientific advice on the appropriate evidence standards for non-prescription health products containing cannabis.
Health Canada is establishing a Science Advisory Committee on Health Products Containing Cannabis (called "the Committee").
The Committee will provide independent scientific and clinical advice to support the Department's consideration of appropriate safety, efficacy, and quality standards for health products containing cannabis. This includes the conditions under which these products would be suitable to be used without practitioner oversight (such as dose and indication). The Committee will have a one-year term with option of renewal based on the Department's needs.
Terms of Reference
- November 2 and 3, 2020 agenda
- November 30 and December 2, 2020 agenda
- January 19, 2021 agenda (Subcommittee meeting)
- March 3, 2021 agenda
- June 17, 2021 agenda
- July 27, 2021 agenda (Subcommittee meeting)
- July 30, 2021 agenda
- September 2, 2021 agenda
- October 4, 2021 agenda
- October 7, 2021 agenda (Subcommittee meeting)
- November 5, 2021 agenda
- December 10, 2021 agenda
- Date modified: